Patrick Soon-Shiong
Patrick Soon-Shiong is a South African-American surgeon, medical researcher, businessman, and philanthropist. He is the inventor of the drug Abraxane, which became known for its efficacy against lung, breast, and pancreatic cancer. Soon-Shiong is the founder of NantWorks, a network of healthcare, biotech, and artificial intelligence startups. He is also the owner of the Los Angeles Times and The San Diego Union-Tribune.
Early life and education
Soon-Shiong was born in Port Elizabeth, South Africa, to Chinese immigrant parents who fled from China during the Japanese occupation in World War II. He completed his medical degree at the University of Witwatersrand and his surgical residency at the University of British Columbia.
Career
Soon-Shiong joined the UCLA Medical School faculty in 1983, where he performed the first full pancreas transplant and developed the first encapsulated human islet transplant and the first pig to man islet cell transplant in diabetic models.
In 1991, he founded a biotechnology firm called Abraxis BioScience. The company developed the drug Abraxane, which is used in the treatment of breast cancer, lung cancer, and pancreatic cancer. Abraxis BioScience was sold to Celgene in 2010.
In 2011, Soon-Shiong founded NantWorks, LLC. The company encompasses businesses across multiple sectors, including healthcare, biotech, and artificial intelligence.
In 2018, Soon-Shiong purchased the Los Angeles Times and The San Diego Union-Tribune.
Philanthropy
Soon-Shiong has made significant contributions to various causes, including healthcare, education, and the arts. He has pledged to give away at least half of his wealth to philanthropy, following the Giving Pledge campaign by Bill Gates and Warren Buffett.
Personal life
Soon-Shiong is married to Michele B. Chan, an actress and former television news anchor. They have two children and reside in Los Angeles, California.
References
<references />
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
